key: cord-0987698-cg53et04
authors: Chauhan, N.; Chahar, A. S.; Singh, P.; Bhavesh, N. S.; Tandon, R.; Chaturvedi, R.
title: SARS-CoV-2 Vaccine-Induced Antibody Response and Reinfection in Persons with Past Natural Infection
date: 2021-05-18
journal: nan
DOI: 10.1101/2021.05.18.21257259
sha: 175924e658a78015a475651667336b36fddb69e3
doc_id: 987698
cord_uid: cg53et04

Several studies have shown that subjects with a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had significantly higher antibody titers than previously uninfected vaccinees after vaccination with mRNA vaccine. Yet no information is available for other vaccines. In the current observational cohort study, 105 health care workers who had received Covishield an Adeno associated viral vector-based DNA vaccine were enrolled at Sarojini Nadu Medical College Agra, India. The study included 40 (23 men and 17 women) subjects with a previous history of SARS-CoV-2 infection and 65 participants (39 men and 26 women) who were not infected previously. Both the groups received the adenovirus vector vaccine ChAdOx1-S recombinant vaccines (Covishield, Astra Zeneca). The levels of SARS-CoV-2-anti-spike-IgG-antibodies titer were measured using Electrochemiluminescence immunoassay on Roche platform as arbitrary units per milliliter (AU/ml). After 28 days of the second dose, subjects with no previous SARSCoV-2 infection showed a significantly lower level of circulating anti-spike-IgG-antibody titers compared to previously infected participants. After the second dose, we also observed a significant increase in SARS-CoV-2 infection in subjects with no prior history of SARS-CoV-2 infection compared to subjects with a previous history of natural infection. The most important observation of the study is a low percentage of infection in previously infected subjects. The finding of the study also indicates the presence of robust humoral memory response in previously infected patients.

Several studies have shown that subjects with a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had significantly higher antibody titers than previously uninfected vaccinees after vaccination with mRNA vaccine. Yet no information is available for other vaccines.

In the current observational cohort study, 105 health care workers who had received Covishield an Adeno associated viral vector-based DNA vaccine were enrolled at Sarojini Nadu Medical College Agra, India.

The study included 40 (23 men and 17 women) subjects with a previous history of SARS-CoV-2 infection and 65 participants (39 men and 26 women) who were not infected previously. Both the groups received the adenovirus vector vaccine ChAdOx1-S recombinant vaccines (Covishield, Astra Zeneca).

The levels of SARS-CoV-2-anti-spike-IgG-antibodies titer were measured using Electrochemiluminescence immunoassay on Roche platform as arbitrary units per milliliter (AU/ml).

After 28 days of the second dose, subjects with no previous SARSCoV-2 infection showed a significantly lower level of circulating anti-spike-IgG-antibody titers compared to previously infected participants.

After the second dose, we also observed a significant increase in SARS-CoV-2 infection in subjects with no prior history of SARS-CoV-2 infection compared to subjects with a previous history of natural infection.

The most important observation of the study is a low percentage of infection in previously infected subjects. The finding of the study also indicates the presence of robust humoral memory response in previously infected patients.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The current study also included 65 participants (39 men and 26 women) who were not infected previously.

The mean age of uninfected participants was 42 ± 1.6 years (95% CI, 38.7 to 44.4).

Both the groups received the adenovirus vector vaccine ChAdOx1-S recombinant vaccines (Covishield, Astra Zeneca). Serum samples were obtained at the day of vaccination (0 days), 28 days after the first and second dose respectively. The levels of SARS-CoV-2-anti-spike-IgG-antibodies titer were measured using Electrochemiluminescence immunoassay on Roche platform as arbitrary units per milliliter (AU/ml) after.

After 28 days of the second dose, subjects with no previous SARSCoV-2 infection showed a significantly lower level of circulating anti-spike-IgG-antibody titers compared to previously infected participants (mean-2881 AU/ml; 95%CI, 2286-3475; mean-540; 95%CI, 318-763 respectively, p<0.0001; Figure 1A ).

All the subjects with previous natural infection showed a significant increase in anti-spike-IgG-antibodies titer level after the second dose compared to pre-vaccination anti-spike-IgG-antibodies titer (mean-3140 AU/ml; 95%CI, 2429-3851; mean-79 AU/ml; 95%CI, 33-124 respectively, p<0.0001; Figure 1B) . We also observed that after the second dose, 22% (14/65) of previously uninfected subjects got infected (mean days for infection post-vaccination; 65 days) with mild symptom in the second wave of pandemic compared to 2.5% in the previously infected group (21/40; P= 0.0082; Figure 1C ). Thirteen subjects out of 14 infected subjects did not show an increase in levels of titers after the second dose compared to the first dose ( Figure 1D ).

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 18, 2021. ; https://doi.org/10.1101/2021.05.18.21257259 doi: medRxiv preprint Discussion: The most important observation of the study is the low percentage of infection in previously infected subjects. The finding of the study also indicates the presence of robust humoral memory response in previously infected patients. This study suggests a need for monitoring the levels of antibody titers in post-vaccinated previously uninfected subjects to achieve a desirable level of protection in a population.

Subjects with lower levels of antibody titer may require a second booster to elevate the antibody levels. 

Covid-19: people who have had infection might only need one dose of mRNA vaccine

Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection